|
1
|
Auersperg N, Wong AS, Choi KC, et al:
Ovarian surface epithelium: biology, endocrinology and pathology.
Endocr Rev. 22:255–288. 2001.PubMed/NCBI
|
|
2
|
Bast RC Jr, Feeney M, Lazarus H, et al:
Reactivity of a monoclonal antibody with human ovarian carcinoma. J
Clin Invest. 68:1331–1337. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Canney PA, Moore M, Wilkinson PM, et al:
Ovarian cancer antigen CA125: a prospective clinical assessment of
its role as a tumour marker. Br J Cancer. 50:765–769. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kabawat SE, Bast RC, Welch WR, et al:
Immunopathologic characterization of a monoclonal antibody that
recognizes common surface antigens of human ovarian tumors of
serous, endometrioid, and clear cell types. Am J Clin Pathol.
79:98–104. 1983.
|
|
5
|
Nap M, Vitali A, Nustad K, Bast RC Jr,
O’Brien TJ, et al: Immunohistochemical characterization of 22
monoclonal antibodies against the CA125 antigen: 2nd report from
the ISOBM TD-1 Workshop. Tumor Biol. 17:325–331. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nustad K, Bast RC Jr, O’Brien TJ, et al:
Specificity and affinity of 26 monoclonal antibodies against the
CA125 antigen: first report from the ISOBM TD-1 workshop.
International Society for Oncodevelopmental Biology and Medicine.
Tumor Biol. 17:196–219. 1996. View Article : Google Scholar
|
|
7
|
Høgdall EV, Christensen L, Kjaer SK, et
al: CA125 expression pattern, prognosis and correlation with serum
CA125 in ovarian tumor patients: from the Danish MALOVA ovarian
cancer study. Gynecol Oncol. 104:508–515. 2007.
|
|
8
|
Ong A, Maines-Bandiera SL, Roskelley CD
and Auersperg N: An ovarian adenocarcinoma line derived from
SV40/E-cadherin-transfected normal human ovarian surface
epithelium. Int J Cancer. 85:430–437. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng J, Mercado-Uribe I, Rosen DG, et al:
Induction of papillary carcinoma in ovarian surface epithelial
cells using combined genetic elements and peritoneal
microenvironment. Cell Cycle. 9:140–146. 2010. View Article : Google Scholar
|
|
10
|
Bast RC Jr, Klug TL, St John E, et al: A
radioimmunoassay using a monoclonal antibody to monitor the course
of epithelial ovarian cancer. N Eng J Med. 309:883–887. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vergote IB, Børmer OP and Abeler VM:
Evaluation of serum CA 125 levels in the monitoring of ovarian
cancer. Am J Obstet Gynecol. 157:88–92. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bafna S, Kaur S and Batra SK:
Membrane-bound mucins: the mechanistic basis for alteration of the
growth and survival of cancer cells. Oncogene. 29:2893–2904. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin BW and Lloyd KO: Molecular cloning of
the CA125 ovarian cancer antigen: identification as a new mucin
(Muc16). J Biol Chem. 276:27371–27375. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin BW, Dnistrian A and Lloyd KO: Ovarian
cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J
Cancer. 98:737–740. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O’Brien TJ, Beard JB, Underwood LJ, et al:
The CA125 gene: an extracellular superstructure dominated by
repeated sequences. Tumour Biol. 22:348–366. 2001.PubMed/NCBI
|
|
16
|
O’Brien TJ, Beard JB, Underwood LJ and
Shigemasa K: The CA125 gene: a newly discovered extension of the
glycosylated N-terminal domain doubles the size of this
extracellular superstructure. Tumour Biol. 23:154–169.
2002.PubMed/NCBI
|
|
17
|
de los Frailes MT, Stark S, Jaeger W, et
al: Purification and characterization of the CA 125
tumor-associated antigen from human ascites. Tumor Biol. 14:18–29.
1993.PubMed/NCBI
|
|
18
|
Kobayashi H, Ida W, Terao T and Kawashima
Y: Molecular characteristics of the CA 125 antigen produced by
human endometrial epithelial cells: comparison between eutopic and
heterotopic epithelial cells. Am J Obstet Gynecol. 169:725–730.
1993. View Article : Google Scholar
|
|
19
|
Fendrick JL, Staley KA, Gee MK, et al:
Characterization of CA 125 synthesized by the human epithelial
amnion WISH cell line. Tumor Biol. 14:310–318. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagata A, Hirota N, Sakai T, et al:
Molecular nature and possible presence of a membranous
glycan-phosphatidylinositol anchor of CA125 antigen. Tumor Biol.
12:279–286. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fendrick JL, Konishi I, Geary SM, et al:
CA125 phosphorylation is associated with its secretion from the
WISH human amnion cell line. Tumor Biol. 18:278–289. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seelenmeyer C, Wegehingel S, Lechner J and
Nickel W: The cancer antigen CA125 represents a novel counter
receptor for galectin-1. J Cell Sci. 116:1305–1318. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perillo NL, Marcus ME and Baum LG:
Galectins: versatile modulators of cell adhesion, cell
proliferation, and cell death. J Mol Med. 76:402–412. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rump A, Morikawa Y, Tanaka M, et al:
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin
mediates cell adhesion. J Biol Chem. 279:190–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gubbels JA, Belisle J, Onda M, et al:
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent
interaction that facilitates peritoneal metastasis of ovarian
tumors. Mol Cancer. 5:502006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patankar MS, Jing Y, Morrison JC, et al:
Potent suppression of natural killer cell response mediated by the
ovarian tumor marker CA125. Gynecol Oncol. 99:704–713. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gubbels JA, Felder M, Horibata S, et al:
MUC16 provides immune protection by inhibiting synapse formation
between NK and ovarian tumor cells. Mol Cancer. 9:112010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Belisle JA, Gubbels JA, Raphael CA, et al:
Peritoneal natural killer cells from epithelial ovarian cancer
patients show an altered phenotype and bind to the tumour marker
MUC16 (CA125). Immunol. 122:418–429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Belisle JA, Horibata S, Jennifer GA, et
al: Identification of Siglec-9 as the receptor for MUC16 on human
NK cells, B cells, and monocytes. Mol Cancer. 9:1182010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boivin M, Lane D, Piché A and Rancourt C:
CA125 (MUC16) tumor antigen selectively modulates the sensitivity
of ovarian cancer cells to genotoxic drug-induced apoptosis.
Gynecol Oncol. 115:407–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matte I, Lane D, Boivin M, et al: MUC16
mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing
TRAIL receptor R2 expression and increasing c-FLIP expression. BMC
Cancer. 14:2342014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thériault C, Pinard M, Comamala M, et al:
MUC16 (CA125) regulates epithelial ovarian cancer cell growth,
tumorigenesis and metastasis. Gynecol Oncol. 121:434–443.
2011.PubMed/NCBI
|
|
33
|
Piché A, Grim J, Rancourt C, et al:
Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2
single-chain antibody increases drug-induced cytotoxicity in the
breast cancer cell line MCF-7. Cancer Res. 58:2134–2140.
1998.PubMed/NCBI
|
|
34
|
Kasono K, Heike Y, Xiang J, et al:
Tetracycline-induced expression of an anti-c-Myb single-chain
antibody and its inhibitory effect on proliferation of the human
leukemia cell line K562. Cancer Gene Ther. 7:151–159. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zietarska M, Maugard CM, Filali-Mouhim A,
et al: Molecular description of a 3D in vitro model for the study
of epithelial ovarian cancer (EOC). Mol Carcinog. 46:872–885. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
et al: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar
|
|
38
|
Bedrosian I, Lu KH, Verschraegen C and
Keyomarsi K: Cyclin E deregulation alters the biologic properties
of ovarian cancer cells. Oncogene. 23:2648–2657. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Comamala M, Pinard M, Thériault C, et al:
Downregulation of cell surface CA125/MUC16 induces
epithelial-to-mesenchymal transition and restores EGFR signaling in
NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer. 104:989–999. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Liu D, Chen D, et al: Human DF3/MUC1
carcinoma-associated protein functions as an oncogene. Oncogene.
22:6107–6110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bafna S, Singh AP, Moniaux N, et al: MUC4,
a multifunctional transmembrane glycoprotein, induces oncogenic
transformation of NIH3T3 mouse fibroblast cells. Cancer Res.
68:9231–9238. 2008. View Article : Google Scholar
|
|
42
|
Satoh S, Hinoda Y, Hayashi T, et al:
Enhancement of metastatic properties of pancreatic cancer cells by
MUC1 gene encoding an anti-adhesion molecule. Int J Cancer.
88:507–518. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singh AP, Moniaux N, Chauhan SC, et al:
Inhibition of MUC4 expression suppresses pancreatic tumor cell
growth and metastasis. Cancer Res. 64:622–630. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Komatsu M, Jepson S, Arango ME, et al:
Muc4/sialomucin complex, an intramembrane modulator of
ErbB2/HER2/Neu potentiates primary tumor growth and suppresses
apoptosis in a xenotransplanted tumor. Oncogene. 20:461–470. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sasaki R, Narisawa-Saito M, Yugawa T, et
al: Oncogenic transformation of human ovarian surface epithelial
cells with defined cellular oncogenes. Carcinogenesis. 30:423–431.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mullany LK, Fan HY, Liu Z, et al:
Molecular and functional characteristics of ovarian surface
epithelial cells transformed by KrasG12D and loss of Pten in a
mouse model in vivo. Oncogene. 30:3522–3536. 2011. View Article : Google Scholar : PubMed/NCBI
|
